Ubenimex (Figure 7, 48) as a CD13 inhibitor overcomes the resistance of cisplatin (CDDP) and improves the sensitivity of GC cells to CDDP by autophagy through perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis (Guo et al., 2019). Here, PIK3CG is linked to gastric cancer.